Logwin AG

  • WKN: A2DR54
  • ISIN: LU1618151879
  • Land: Luxemburg

Nachricht vom 07.06.2021 | 10:06

Logwin AG: Announcement pursuant to Article 5 (1b) and (3) of Regulation (EU) No. 596/2014 and Art. 2 (2) and (3) of Commission Delegated Regulation (EU) No. 2016/1052

Logwin AG / Release of a capital market information
07.06.2021 / 10:06
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Announcement pursuant to Article 5 (1b) and (3) of Regulation (EU) No. 596/2014 and Art. 2 (2) and (3) of Commission Delegated Regulation (EU) No. 2016/1052

Acquisition of treasury shares - 55. Interim Announcement

In the period from 31 May 2021 through 4 June 2021, in total 61 shares were acquired as part of the Logwin AG share buyback program. The start of the share buyback program was announced on 17 March 2020 for 18 March 2020 pursuance of Article 5 (1) a) of Regulation (EU) No. 596/2014 and Article 2 (1) of the Commission Delegate Regulation (EU) No. 2016/1052.

Shares were acquired as follows:

Date Total number of
shares acquired
average price (Euro)
31 May 2021 30 190.3333
1 June 2021 0 0.0000
2 June 2021 0 0.0000
3 June 2021 0 0.0000
4 June 2021 31 197.0000

The total number of shares acquired so far in the period from 18 March 2020 through 4 June 2021 in the course of the share repurchase amounts to 4,194 shares.

The share buyback was carried out by an independent bank of Logwin AG exclusively via the stock exchange in the electronic XETRA trading system of the Frankfurt Stock Exchange.

Information on the individual transactions and on the daily trading volume referred to in Article 5 (1b), (3) of Regulation (EU) No. 596/2014 in connection with Article 2 (2) and (3) of Commission Delegate Regulation (EU) No. 2016/1052 are published on the internet at the following link:


Grevenmacher, 7 June 2021

Logwin AG
The Board of Directors

07.06.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie


Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021